ZA918712B - Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative - Google Patents

Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative

Info

Publication number
ZA918712B
ZA918712B ZA918712A ZA918712A ZA918712B ZA 918712 B ZA918712 B ZA 918712B ZA 918712 A ZA918712 A ZA 918712A ZA 918712 A ZA918712 A ZA 918712A ZA 918712 B ZA918712 B ZA 918712B
Authority
ZA
South Africa
Prior art keywords
tnf
antibody
xanthine derivative
xanthine
range
Prior art date
Application number
ZA918712A
Other languages
English (en)
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Heinz Hanel
Michael Limbert
Mark William Bodmer
Gerald Anthony Higgs
Original Assignee
Celltech Ltd
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd, Hoechst Ag filed Critical Celltech Ltd
Publication of ZA918712B publication Critical patent/ZA918712B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA918712A 1990-11-01 1991-11-01 Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative ZA918712B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023783A GB9023783D0 (en) 1990-11-01 1990-11-01 Pharmaceutical product

Publications (1)

Publication Number Publication Date
ZA918712B true ZA918712B (en) 1992-09-30

Family

ID=10684716

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA918712A ZA918712B (en) 1990-11-01 1991-11-01 Pharmaceutical product comprising an antibody to tnf or a tnf binding fragment thereof and a xanthine derivative

Country Status (15)

Country Link
EP (1) EP0564461B1 (de)
JP (1) JP3468515B2 (de)
KR (1) KR930701970A (de)
AT (1) ATE146971T1 (de)
AU (1) AU653180B2 (de)
CA (1) CA2094154A1 (de)
DE (1) DE69123984T2 (de)
DK (1) DK0564461T3 (de)
ES (1) ES2096662T3 (de)
GB (1) GB9023783D0 (de)
GR (1) GR3022210T3 (de)
HU (1) HUT70267A (de)
NO (1) NO931580D0 (de)
WO (1) WO1992007585A1 (de)
ZA (1) ZA918712B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994008619A1 (en) * 1992-10-08 1994-04-28 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AU1090795A (en) 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DK0942740T3 (da) * 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
EP1352656A3 (de) * 1996-12-06 2004-02-04 Amgen Inc. Kombinationtherapie mit einem tnf-bindendem Protein zür behandlung von durch tnf verursachten Erkrangungen
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
DE69123984D1 (de) 1997-02-13
NO931580D0 (no) 1993-04-30
HUT70267A (en) 1995-09-28
ES2096662T3 (es) 1997-03-16
GR3022210T3 (en) 1997-04-30
AU653180B2 (en) 1994-09-22
ATE146971T1 (de) 1997-01-15
JP3468515B2 (ja) 2003-11-17
GB9023783D0 (en) 1990-12-12
DE69123984T2 (de) 1997-05-22
CA2094154A1 (en) 1992-05-02
AU8758391A (en) 1992-05-26
DK0564461T3 (da) 1997-01-20
KR930701970A (ko) 1993-09-08
HU9301093D0 (en) 1993-07-28
EP0564461B1 (de) 1997-01-02
WO1992007585A1 (en) 1992-05-14
EP0564461A1 (de) 1993-10-13
JPH06502629A (ja) 1994-03-24

Similar Documents

Publication Publication Date Title
NO175042C (de)
GR3033144T3 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases.
GB9023783D0 (en) Pharmaceutical product
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
NL194748B (nl) Osmotische doseringsvorm voor behandeling van cardiovasculaire ziekten.
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
IL103981A0 (en) Pharmaceutical compositions for treatment of multiple sclerosis
EP1941904A3 (de) Anti-TNF-Antikörper und Methotrexat bei der Behandlung von Autoimmunkrankheiten
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
CA2273852A1 (en) Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
HUT76875A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
NZ241211A (en) 16alpha,17alpha-alkylidenedioxy-11b,21-dihydroxypregan -4-ene-3,20-dione derivatives substituted by halogen in either or both of the 6alpha- or the 9alpha- position; pharmaceutical compositions, methods of preparation and treatment
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
TW197423B (de)
EP0417003A3 (en) Use of antiprogestomimetics for stimulating ovulation
ZA882504B (en) Use of antigenic substances for the prophylaxis or therapy of disorders and diseases within the gastrointestinal tract of animals and humans
NL187299C (nl) Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten.
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
Ancill et al. Oral caffeine augmentation of ECT.
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms